Infectious Disease · Medical Literature
[News] WHO prequalifies novel polio vaccine
Abstract
On Feb 10, 2026, WHO prequalified a novel oral polio vaccine type 2 (nOPV2; Biological E [BioE], India). The product was developed following a technology transfer from PT Bio Farma (Indonesia). Designed to address outbreaks of circulating vaccine-derived poliovirus type 2 (cVDPV2), the vaccine strengthens the global tools available against type 2 poliovirus in under-immunised populations.
Clinical relevance
Does WHO prequalification of a second manufacturer's novel oral polio vaccine type 2 (nOPV2; Biological E, India) strengthen global supply capacity and outbreak response capability against circulating vaccine-derived poliovirus type 2 (cVDPV2)? __SNAPSHOT__ {"studyDesign":"News report / regulatory milestone commentary (not a primary clinical trial or systematic review); reports a WHO prequalification decision dated February 10, 2026, published in The Lancet Microbe on April 8, 2026","setting":"Global public health / regulatory context; manufacturer located in Hyderabad, India (Biological E. Limited); technology transferred from PT Bio Farma, Indonesia","sampleSize":"Not applicable (regulatory commentary, not a clinical study). Supporting clinical evidence base includes: >2 billion nOPV2 doses administered globally across >35 countries since March 2021; Phase 3 RCT safety/immunogenicity data from The Gambia and Dominican Republic; Phase 1–2 trials in Belgium, Panama, and Bangladesh","population":"Children aged 0–5 years in under-immunized populations at risk of cVDPV2 outbreaks, primarily in Africa and Asia; nOPV2 is designated for outbreak response supplementary immunization activities (SIAs), not routine childhood immunization","intervention":"nOPV2 manufactured by Biological E. Limited (India) using in-house bulk vaccine following technology transfer from PT Bio Farma; supplied in 20-dose and 50-dose vials; shelf life 24 months at ≤−20°C or up to 6 months at +2°C to +8°C; opened vials usable up to 28 days per WHO Multi-dose Vial Policy","comparator":"Implicitly compared to prior nOPV2 supply sourced solely from PT Bio Farma (Indonesia); historically compared to monovalent oral poliovirus vaccine type 2 (mOPV2) for genetic stability and outbreak prevention","primaryOutcome":"WHO prequalification confirmation that the BioE nOPV2 product meets international standards of quality, safety, and efficacy, enabling UN procurement (including UNICEF); secondary public health outcome: expansion of global supply security and outbreak response capacity","followUp":"Not applicable (regulatory milestone report); real-world nOPV2 field use has been monitored continuously since March 2021","fundingSource":"Original nOPV2 clinical development funded by the Bill & Melinda Gates Foundation; nOPV2 procured under GPEI coordination; funding for BioE manufacturing scale-up not reported in this article"}
Key findings
This Lancet Microbe news article reports that on February 10, 2026, WHO granted prequalification to nOPV2 manufactured by Biological E. (India), making BioE the second fully qualified manufacturer of nOPV2 alongside PT Bio Farma. BioE is expected to produce up to 600 million doses annually, augmenting the existing global stockpile. The clinical evidence supporting nOPV2 prequalification—accumulated prior to this article—is substantial: across >2 billion administered doses in >35 countries since March 2021, GPEI data indicate an estimated ~80% reduction in new cVDPV2 outbreak emergence compared with equivalent use of mOPV2 (this figure is reported by GPEI/WHO; absolute event counts: 10 cVDPV2 emergences from nOPV2 vs. an estimated 66 that would have been seeded by mOPV2 at equivalent scale). Phase 3 RCT data from The Gambia showed seroconversion in approximately two-thirds of seronegative infants after one dose and >80% after two doses; baseline type 2 seroprotection rates of ~75% increased to 92–96% following two doses. Adverse event rates were comparable to bivalent OPV, with no new safety signals identified across Phase 3 trials or post-authorization surveillance in multiple countries. Approximately 70% of countries demonstrated no evidence of breakthrough cVDPV2 transmission following two rounds of nOPV2 SIAs—comparable to the performance of mOPV2. The real-world Malawi example cited in this article is illustrative: following detection of a cVDPV2 case in January 2026, a campaign targeting ~1.3 million children across 8 districts achieved ~97% coverage within 4 days using 1.7 million nOPV2 doses. No trial-level NNT or NNH was calculable from this news item alone.
Practice implications
This article establishes a supply chain and regulatory milestone, not a new efficacy or safety finding. The prequalification of a second nOPV2 manufacturer (BioE) expands global production capacity and reduces supply concentration risk—operationally critical given that cVDPV2 outbreaks require rapid deployment of large vaccine volumes. The accumulated evidence base for nOPV2 (Phase 1–3 clinical trials in Belgium, Panama, Bangladesh, The Gambia, and Dominican Republic; post-authorization surveillance across 35+ countries with >2 billion doses) robustly supports its safety, immunogenicity, and superior genetic stability versus mOPV2. The findings most directly apply to children aged 0–5 years in cVDPV2-affected, under-immunized populations in low- and middle-income settings. Populations in high-income countries using inactivated polio vaccine (IPV) exclusively are not represented and are not the intended recipients. Clinicians and public health practitioners should note that nOPV2 remains designated for outbreak response SIAs only and is not a substitute for routine IPV or bivalent OPV immunization. The clinical significance of expanded manufacturing capacity lies in enabling faster, concurrent outbreak responses globally. This article is a regulatory news item only; original data are not presented. Efficacy and safety conclusions are drawn from the cited supporting evidence base, not from this publication itself. __LIMITATIONS__ 1. Study design: This is a news/commentary item, not a primary research study; no new efficacy, safety, or immunogenicity data are reported. All quantitative claims derive from pre-existing surveillance and clinical trial data. 2. Abstract-only context: Only the provided abstract was submitted; supporting quantitative estimates are drawn from the broader literature via web search and are not sourced from this specific article. 3. Outbreak prevention estimates (~80% reduction in cVDPV2 emergence vs. mOPV2) are based on observational post-authorization data and modeled comparisons to a historical counterfactual, not a randomized head-to-head trial, introducing potential confounding and bias. 4. Generalizability: nOPV2 field evidence is concentrated in Sub-Saharan Africa; data from other endemic or outbreak-prone regions are less robust. 5. Long-term genetic stability of nOPV2 under very large-scale use continues to require surveillance; rare reversion events have been documented (e.g., Uganda, 2025). 6. This article does not report BioE product-specific immunogenicity or safety data; the regulatory finding is based on comparability to the PT Bio Farma product. 7. Funding and conflict of interest details for this specific report are not provided. __BOTTOM_LINE_CATEGORY__ potentially_practice_informing __BOTTOM_LINE__ WHO prequalification of nOPV2 manufactured by Biological E. (India) adds a second fully qualified global supplier capable of producing up to 600 million doses annually, directly addressing the supply vulnerability that constrains rapid cVDPV2 outbreak response. The nOPV2 evidence base—spanning Phase 1–3 trials and >2 billion administered doses—supports its safety, immunogenicity, and an estimated ~80% reduction in new vaccine-derived outbreak emergence versus mOPV2. For public health practitioners and clinicians involved in outbreak response, this development represents a meaningful operational advance in global polio eradication strategy, though it does not alter existing clinical guidance for routine immunization programs.